Gyre Therapeutics Inc (GYRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Sales | 22,519 | 37,195 | 30,564 | 26,771 | 22,058 |
| Cost of Goods | 1,227 | 1,743 | 1,628 | 1,151 | 894 |
| Gross Profit | 21,292 | 35,452 | 28,936 | 25,620 | 21,164 |
| Operating Expenses | 30,874 | 36,079 | 22,637 | 23,600 | 19,785 |
| Operating Income | -9,355 | 118 | 6,925 | 2,171 | 2,273 |
| Other Income | 118 | -184 | 704 | 67 | 2,362 |
| Pre-tax Income | -9,237 | -66 | 7,629 | 2,238 | 4,635 |
| Income Tax | 621 | 1,300 | 1,693 | 662 | 901 |
| Net Income Continuous | -9,858 | -1,366 | 5,936 | 1,576 | 3,734 |
| Minority Interests | -1,167 | 357 | 2,326 | 1,134 | 1,036 |
| Net Income | $-8,691 | $-1,723 | $3,610 | $442 | $2,698 |
| EPS Basic Total Ops | -0.10 | -0.01 | 0.04 | 0.00 | 0.03 |
| EPS Basic Continuous Ops | -0.11 | -0.02 | 0.07 | 0.02 | 0.04 |
| EPS Diluted Total Ops | -0.10 | -0.01 | 0.03 | 0.00 | 0.00 |
| EPS Diluted Continuous Ops | -0.11 | -0.01 | 0.06 | 0.02 | 0.04 |
| EPS Diluted Before Non-Recurring Items | -0.08 | 0.04 | 0.05 | 0.02 | 0.00 |
| EBITDA(a) | $-8,683 | $811 | $7,576 | $2,812 | $2,808 |